Sio Capital Management’s Travere Therapeutics TVTX Stock Holding History

Sio Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-122,210	Closed	-$1.81M	–	64
2025 Q2	$1.81M	Buy	122,210 +1,210	+1%	+$20.1K	0.69%	32
2025 Q1	$2.17M	Buy	+121,000	New	+$2.46M	0.65%	31
2023 Q4	–	Sell	-884,770	Closed	-$7.91M	–	58
2023 Q3	$7.91M	Buy	+884,770	New	+$12.5M	2.45%	17
2021 Q3	–	Sell	-150,000	Closed	-$2.19M	–	79
2021 Q2	$2.19M	Buy	+150,000	New	+$2.96M	0.54%	52

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Sio Capital Management's TVTX Position: Q3 2025 in Review

Sio Capital Management sold out of Travere Therapeutics (TVTX) in Q3 2025, closing a stake of 122,210 shares — an estimated $1.81M sold.

Sio Capital Management first reported a position in TVTX in Q2 2021 and held it in 4 quarters. The position peaked at $7.91M in Q3 2023. 238 funds tracked by Wall St. Rank hold TVTX as of Q3 2025.

Sio Capital Management reported no remaining Travere Therapeutics position as of Q3 2025 after selling out during the quarter.
Sio Capital Management sold 122,210 Travere Therapeutics shares in Q3 2025, an estimated $1.81M.
Sio Capital Management first reported a position in Travere Therapeutics in Q2 2021 and held it in 4 quarters.
Sio Capital Management's Travere Therapeutics position peaked at $7.91M in Q3 2023.
238 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2025.

Based on Sio Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.